GlassScriptPhysician profile
Matthew J Knudson
NPI 1962609768
$4,134.30
in general payments reported to CMS, 2019-2025
30 companies · $638 in 2025
The $638 reported for 2025 was less than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $780 · 2020: $210 · 2021: $229 · 2022: $873 · 2023: $1,009 · 2024: $396 · 2025: $638.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,785 · Honoraria: $258.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,785.26 |
| Honoraria | $257.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axonics, INC. | $1,200.25 | 2022-2024 | Axonics, Bulkamid |
| Astellas Pharma US INC | $421.30 | 2019-2024 | Myrbetriq, Veozah |
| 180 Medical, INC. | $287.19 | 2019-2023 | Gentlecath Glide |
| Convatec INC. | $278.14 | 2021-2024 | |
| Pfizer INC. | $258.17 | 2019-2025 | |
| Boston Scientific Corporation | $165.35 | 2019-2025 | Axonics, Bulkamid, Spaceoar Vue System - 10ml |
| Janssen Biotech, INC. | $143.27 | 2019-2025 | Erleada |
| Abbvie INC. | $137.16 | 2019-2023 | |
| Olympus America INC. | $136.30 | 2025 | Itind System |
| Neotract INC. | $133.84 | 2019-2020 | |
| Endo Pharmaceuticals INC. | $110.54 | 2021-2024 | Edex, Aveed, Xiaflex |
| Coloplast Corp | $95.37 | 2020-2025 | Speedicath |
| Antares Pharma, INC. | $95.25 | 2019-2020 | |
| Endo USA, INC. | $91.90 | 2025 | Xiaflex, Edex, Aveed |
| Teleflex LLC | $90.60 | 2021-2024 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Hollister Incorporated | $76.32 | 2022 | |
| Merck Sharp & Dohme LLC | $67.41 | 2019-2025 | Keytruda, Lynparza, Welireg |
| Allergan, INC. | $64.58 | 2019-2021 | |
| Sumitomo Pharma America, INC. | $56.92 | 2024-2025 | Orgovyx, Gemtesa |
| Calyxo, INC. | $44.74 | 2024-2025 | Cvac Aspiration System |
| Novartis Pharmaceuticals Corporation | $26.87 | 2025 | |
| Welch Allyn | $24.38 | 2021 | |
| Progenics Pharmaceuticals, INC. | $21.21 | 2023 | Pylarify |
| Tolmar, INC. | $19.28 | 2025 | Jatenzo |
| Bayer Healthcare Pharmaceuticals INC. | $17.38 | 2022 | |
| Urogen Pharma, INC. | $16.58 | 2024 | |
| Amgen INC. | $15.11 | 2023 | Prolia, Evenity |
| Accord Healthcare, INC. | $14.41 | 2023 | |
| Karl Storz Endoscopy-America | $13.47 | 2020 | |
| Sun Pharmaceutical Industries INC. | $11.01 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Knudson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.